BioDelivery Sciences readies BEMA for application; pSivida's Iluvien gets Spanish agency nod;

> AstraZeneca ($AZN) has signed up with U.K.-based materials development company Ceram to develop extended-release versions of AstraZeneca compounds. Ceram's controlled-release technologies use glass, ceramics and powder to deliver individual drugs or drug combinations over extended periods. Press release

> BioDelivery Sciences International ($BDSI) has completed the safety study of its BioErodible MucoAdhesive (BEMA) formulation of buprenorphine and naloxone, known as BNX. According to the company, it's still on track for a midyear new drug application submission. Press release

> Omeros finished its Phase III trial for OMS302, which eases the pain and discomfort of cataract and other lens-replacement surgery. Press release

> Velocity Pharmaceutical Development and EuMederis Pharmaceuticals have joined forces to improve the overall handling of peptides, including their delivery. Report

> The Spanish Agency of Drugs granted marketing authorization to pSivida ($PSDV), a sustained-release drug company, for Iluvien, designed to treat vision impairment associated with chronic diabetic macular edema. Report

> The FDA issued a complete response letter for the NDA of Rytary extended-release capsules by Impax Laboratories ($IPXL). The agency stated that it would require a re-inspection of the company's facility before the NDA can be approved. Press release

Suggested Articles

Kala Pharma's Eysuvis on Tuesday became the first and only corticosteroid approved to treat short-term signs and symptoms of dry eye disease.

Xeris scored an FDA fast track designation for its diazepam formulation, delivered via autoinjector, to treat acute repetitive seizures.

Armed with microrobots and magnetic fields, Pursue scientists are looking to the future of targeted drug delivery, starting with the colon.